ViaDerma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher A Otiko
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4640 Admiralty Way Marina del Rey CA United States of America 90292
- IPO Date
- Oct 31, 2014
- CIK
- 0001435717
- Website
- viadermalicensing.com
- Similar Companies
- Business
- ViaDerma, Inc. (OTC Pink: VDRM) operates as a specialty pharmaceutical company focused on developing, manufacturing, and marketing topical pharmaceutical products utilizing its patent-pending SkinPassTM transdermal drug delivery system technology. The company offers Vitastem, a tetracycline-based topical antibiotic for over-the-counter use in treating cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries; it also pursues products in fields including topical antibiotics, toenail antifungals, diabetic wound care, anti-aging creams, medical cannabis applications, male-pattern baldness treatments, skin cancer therapies, erectile dysfunction solutions, and pain management via the SkinPassTM platform, with licensing opportunities to other pharmaceutical firms. Founded in 2007 and headquartered in Marina del Rey, California, with remote-first operations, research facilities, and offices spanning North America, Europe, Asia, and the Middle East, ViaDerma targets consumer and professional wound care markets globally. In recent developments, the company finalized distribution agreements in Dubai for Vitastem with leading Middle East and Eastern Europe partners in August 2024, enabling supply to private and government entities; completed a one-million-unit order to Nigeria in two shipments during August and October 2024; expanded licensing agreements with a home health wound care network across six U.S. states and a group of affiliate wound care practices; hired six key executives including a business development analyst, project manager, HR specialist, fractional COO, regulatory specialist, and chief technology officer in mid-2024 to support global expansion; and grew its workforce to 13 employees across seven countries while confirming ongoing operations and regulatory compliance in June 2025.
ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria
ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires
ViaDerma Provides Highlights of Quarterly Financial Report
ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More
ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra
ViaDerma, Inc. Files Amended Financial Statements
ViaDerma, Inc. Provides Updates on Current Business Activities
ViaDerma, Inc. Announces Expansion of its Current Licensing Agreement and Provides Additional Company Updates
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network
ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record Breaking 1st Quarter
ViaDerma, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States
VDRM Stock: 13 Things to Know as Penny Stock ViaDerma Rockets 1,000%